OmniAb (OABI)

Executive Summary

OmniAb, Inc. (NASDAQ: OABI) is a leading antibody discovery platform company that provides pharmaceutical partners with access to its proprietary transgenic animal systems and Biological Intelligence™ platform to generate fully human therapeutic antibodies and peptides. The company's technology leverages the natural immune systems of genetically engineered animals to produce highly diverse and optimized antibody repertoires, enabling the development of next-generation biologics across a broad range of diseases. Since its public listing via SPAC in 2022, OmniAb has built a robust partnership model, generating revenue primarily through license fees, milestones, and royalties on partnered programs. The platform's value proposition lies in its ability to accelerate drug discovery, reduce risk, and improve the quality of antibody candidates, making it a key enabler for biopharma companies. Looking ahead, OmniAb is well-positioned to benefit from the growing demand for novel biologics and the increasing outsourcing of discovery capabilities to specialized platforms. The company continues to expand its technology suite and forge new collaborations, with several partnered programs advancing through preclinical and early clinical stages. Financially, OmniAb maintains a solid balance sheet to support operations and platform investments. Key near-term drivers include the signing of new partnership agreements, the expansion of existing alliances, and potential updates on the progress of partnered molecules. While the platform model inherently involves reliance on partner execution and milestone timing, OmniAb's diversified portfolio of partnerships provides a foundation for sustainable growth.

Upcoming Catalysts (preview)

• Q3 2026New pharmaceutical partnership announcement75% success
• Q4 2026Launch of next-generation transgenic platform or technology upgrade60% success
• TBDPositive clinical data readout for a partnered antibody program40% success